/ /

  • linkedin
  • Increase Font
  • Sharebar

    Drug therapies improving refractive outcomes

    Take-home message: Advances in cataract research and therapies such as new alternatives to topical drops are becoming common in ophthalmologist’s strategies.




    Lines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds—phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)—are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.

    “I’m no longer using topical antibiotics after cataract surgery. This is the year that my practice changed in that respect,” said Robert K. Maloney, MD, Los Angeles. “The evidence in the literature is very clear that intracameral antibiotics reduce the risk of infections, and there's really no evidence that topical antibiotics reduce the risk of infection.”

    Especially as the price of generic topical antibiotics has increased, “there’s a real advantage for a patient in finding alternatives to topical drops,” he said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results